ATE512151T1 - Pyrrolotriazin-kinaseinhibitoren - Google Patents

Pyrrolotriazin-kinaseinhibitoren

Info

Publication number
ATE512151T1
ATE512151T1 AT06837967T AT06837967T ATE512151T1 AT E512151 T1 ATE512151 T1 AT E512151T1 AT 06837967 T AT06837967 T AT 06837967T AT 06837967 T AT06837967 T AT 06837967T AT E512151 T1 ATE512151 T1 AT E512151T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
formula
pyrrolotriazine kinase
pyrrolotriazine
trkc
Prior art date
Application number
AT06837967T
Other languages
English (en)
Inventor
Ping Chen
Yufen Zhao
Brian Fink
Soong-Hoon Kim
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE512151T1 publication Critical patent/ATE512151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06837967T 2005-11-18 2006-11-17 Pyrrolotriazin-kinaseinhibitoren ATE512151T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73826905P 2005-11-18 2005-11-18
US11/560,378 US7514435B2 (en) 2005-11-18 2006-11-16 Pyrrolotriazine kinase inhibitors
PCT/US2006/044756 WO2007061882A2 (en) 2005-11-18 2006-11-17 Pyrrolotriazine kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE512151T1 true ATE512151T1 (de) 2011-06-15

Family

ID=38051768

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06837967T ATE512151T1 (de) 2005-11-18 2006-11-17 Pyrrolotriazin-kinaseinhibitoren

Country Status (9)

Country Link
US (1) US7514435B2 (de)
EP (1) EP1948664B1 (de)
JP (1) JP5095626B2 (de)
KR (1) KR101392678B1 (de)
CN (1) CN101365701B (de)
AT (1) ATE512151T1 (de)
AU (1) AU2006318682B2 (de)
NO (1) NO20082023L (de)
WO (1) WO2007061882A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US8124759B2 (en) * 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
KR20100028068A (ko) * 2007-07-03 2010-03-11 사노피-아벤티스 말단 알킨과 헤테로아릴 토실레이트 및 헤테로아릴 벤젠설포네이트의 팔라듐-촉매되는 커플링 방법
MX2010003269A (es) 2007-09-25 2010-08-02 Bayer Healthcare Llc Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
SI2206707T1 (sl) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
US8445676B2 (en) * 2008-10-08 2013-05-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
US8765754B2 (en) * 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
EP2552922A1 (de) * 2010-03-31 2013-02-06 Bristol-Myers Squibb Company Substituierte pyrrolotriazine als proteinkinasehemmer
NZ618795A (en) 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
WO2013004551A1 (en) * 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
CA2862981C (en) 2011-12-15 2020-02-25 Bayer Pharma Aktiengesellschaft Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
CA2885259A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
ME02990B (de) 2012-11-13 2018-10-20 Array Biopharma Inc N-pyrrolidinyl-, n'-pyrazolyl-harnstoff-, thioharnstoff-, guanidin- und cyanoguanidinverbindungen als trka-kinaseinhibitoren
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
CA2891334C (en) 2012-11-13 2021-10-19 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
CN106459013B (zh) 2014-05-15 2019-10-25 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
CN104151276A (zh) * 2014-06-30 2014-11-19 北京万全德众医药生物技术有限公司 一种盐酸决奈达隆代谢杂质的制备方法
EP3209664B1 (de) 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Bicyclische heteroarylaminverbindungen als pi3k-hemmer
WO2016064958A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
CN112225723B (zh) * 2020-12-16 2021-03-30 北京华氏开元医药科技有限公司 一种吲哚类衍生物、制备方法及应用
EP4335441B1 (de) * 2021-05-03 2025-05-28 JBKLAB Co., Ltd. Pharmazeutische zusammensetzung zur prävention, linderung oder behandlung von krebs mit 2,6-dichlor-4-(4-(4-hydroxycyclohexylamino)-7h-pyrrolo[2,3-d!pyrimidin-5-yl)phenol als wirkstoff

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
IL144977A0 (en) * 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
AU3276002A (en) 2000-11-17 2002-05-27 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US7015231B2 (en) 2001-09-27 2006-03-21 Smithkline Beecham Corporation Chemical compounds
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
ATE418546T1 (de) 2002-04-23 2009-01-15 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI272271B (en) 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
EP1945222B1 (de) * 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamine als igf-1r-kinasehemmer zur behandlung von krebs und anderen hyperproliferativen erkrankungen

Also Published As

Publication number Publication date
CN101365701B (zh) 2011-11-30
AU2006318682A1 (en) 2007-05-31
AU2006318682B2 (en) 2012-04-05
JP5095626B2 (ja) 2012-12-12
WO2007061882A3 (en) 2007-08-16
EP1948664A2 (de) 2008-07-30
KR101392678B1 (ko) 2014-05-07
CN101365701A (zh) 2009-02-11
JP2009515995A (ja) 2009-04-16
WO2007061882A2 (en) 2007-05-31
KR20080079262A (ko) 2008-08-29
US20070149534A1 (en) 2007-06-28
EP1948664B1 (de) 2011-06-08
US7514435B2 (en) 2009-04-07
NO20082023L (no) 2008-08-05

Similar Documents

Publication Publication Date Title
WO2007061882A3 (en) Pyrrolotriazine kinase inhibitors
NL301113I1 (nl) Tucatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
WO2008057994A3 (en) Pyrrolotriazine kinase inhibitors
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MA29136B1 (fr) Agents de potentialisation de recepteurs du glutamate
CY1114539T1 (el) Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
ATE527253T1 (de) Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
DK1761520T3 (da) Kinaseinhibitorer
DE60315270D1 (de) Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
EA200900783A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA200801199A1 (ru) Ингибиторы киназы
ATE482212T1 (de) Pyrrolotriazinverbindungen
EA200601176A1 (ru) 3-цианохинолиновые производные с антипролиферативной активностью
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
ECSP077993A (es) Intermedios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina cinasa y metodos relacionados de sintesis
ATE548364T1 (de) Aminopyrazolkinasehemmer
BRPI0509731A (pt) pirazol[4,3-d]pirimidinas
ATE421510T1 (de) Kompetitive atp-kinasehemmer
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties